Predictors of compliance with antihypertensive therapy in a high-risk medicaid population

Journal of the National Medical Association

Volumn 101, Issue 1, 2009, Pages 34-39

  Shaya, Fadia T ^a   Du, Dongyi ^a   Gbarayor, Confidence M ^a   Frech Tamas, Feride ^b   Lau, Helen ^b   Weir, Matthew R ^c  

^a UNIVERSITY OF MARYLAND SCHOOL OF PHARMACY   (United States)

^b NOVARTIS PHARMA AG   (Switzerland)

^c UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HYDROCHLOROTHIAZIDE;

ADULT; AFRICAN AMERICAN; ARTICLE; CARDIOVASCULAR DISEASE; CAUCASIAN; CLINICAL ASSESSMENT; COMORBIDITY; CONTROLLED STUDY; ETHNICITY; FEMALE; FOLLOW UP; GROUPS BY AGE; HIGH RISK POPULATION; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; MEDICAID; MULTIVARIATE LOGISTIC REGRESSION ANALYSIS; PATIENT COMPLIANCE; PREDICTOR VARIABLE; PRIORITY JOURNAL;

EID: 61449267540     PISSN: 00279684     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0027-9684(15)30808-7     Document Type: Article

References (42)

1. Fields LE, Burt VL, Cutler JA, et al. The burden of adult hypertension in the United States 1999 to 2000: a rising tide. Hypertension. 2004:44:398-404.
2. Ezzati M, Lopez AD, Rodgers A, et al. Selected major risk factors and global and regional burden of disease. Lancet. 2002:360:1347-1360.
3. Chobanian AV, Bakris GL, Black HR, et al. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA. 2003:289:2560-2572.
4. Vasan RS, Beiser A, Seshadri S, et al. Residual lifetime risk for developing hypertension in middle-aged women and men: The Framingham Heart Study. JAMA. 2002;287:1003-1010.
5. Neal B, MacMahon S, Chapman N. Effects of ACE inhibitors, calcium antagonists, and other blood-pressure-lowering drugs: results of prospectively designed overviews of randomised trials. Blood Pressure Lowering Treatment Trialists' Collaboration. Lancet. 2000:356:1955-1964.
6. American Heart Association. Heart and Stroke Statistical Update. In: American Heart Association. Dallas, TX; 1998.
7. American Heart Association. Heart and Stroke Statistical Update-2003. http://www.americanheart.org. Accessed April 12,2007.
8. Rosamond W, Flegal K, Friday G, et al. Heart disease and stroke statistics-2007 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation. 2007:115:e69- 171.
9. Collins R, Peto R, MacMahon S, et al. Blood pressure, stroke, and coronary heart disease, Part 2. Short-term reductions in blood pressure: overview of randomised drug trials in their epidemiological context. Lancet. 1990:335:827-838.
10. He J, Whelton PK. Elevated systolic blood pressure as a risk factor for cardiovascular and renal disease. J Hypertens. 1999:17(suppl):S7-S13.
11. MacMahon S, Peto R, Cutler J, et al. Blood pressure, stroke, and coronary heart disease. Part 1. Prolonged differences in blood pressure: prospective observational studies corrected for the regression dilution bias. Lancet. 1990:335:765-774.
12. Rahman M, Pressel S, Davis BR, et al. Renal outcomes in high-risk hypertensive patients treated with an angiotensin-converting enzyme inhibitor or a calcium channel blocker vs a diuretic: a report from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). Arch Intern Med. 2005:165:936-946.
13. 13.Hajjar I.Kotchen TA. Trends in prevalence, awareness, treatment, and control of hypertension in the United States, 1988-2000. JAMA. 2003:290:199-206.
14. The Centers for Disease Control and Prevention (CDC). Racial/ethnic disparities in prevalence, treatment, and control of hypertension-United States, 1999-2002. MMWR Atorb Mortal Wkly Rep. 2005:54:7-9.
15. Flack JM, Casciano R, Casciano J, et al. Cardiovascular disease costs associated with uncontrolled hypertension. Manag Care Interface. 2002:15:28-36.
16. McCombs JS, Nichol MB, Newman CM, Sclar DA. The costs of interrupting antihypertensive drug therapy in a Medicaid population. Med Care. 1994:32:214-226.
17. Carter BL. Antihypertensive prescribing: do we have reason to celebrate? Hypertension. 2006:48:816-817.
18. Sackett DL. Compliance with therapeutic regimens, ed. Sackett DL, Haynes RB. Baltimore, MD: Johns Hopkins University Press; 1976:1-6.
19. Elzubier AG, Husain AA, Suleiman IA, Hamid ZA. Drug compliance among hypertensive patients in Kassala, eastern Sudan. East Mediter Health J. 2000:6:100-105.
20. Bramley TJ, Gerbino PP, Nightengale BS, Frech-Tamas F. Relationship of blood pressure control to adherence with antihypertensive monotherapy in 13 managed care organizations. J Manag Care Pharm. 2006:12:239-245.
21. Kaiser Commission on Medicaid and the Uninsured. Medicaid Disease Management: Issues and Promises. 2004. http://www.kff.org. Accessed April 12,2007.
22. Robert Wood Johnson F. The faces of Medicaid: the complexities of caring for people with chronic illnesses and disabilities. Princeton, NJ: Center for Health Care Strategies Inc; 2000.
23. Monane M, Bohn RL, Gurwitz JH, et al. Compliance with antihypertensive therapy among elderly Medicaid enrollees: the roles of age, gender, and race. Am J Public Health. 1996:86:1805-1808.
24. Monane M, Bohn RL, Gurwitz JH, et al. The effects of initial drug choice and comorbidity on antihypertensive therapy compliance: results from a population-based study in the elderly. Am J Hypertens. 1997:10:697-704.
25. Kaiser Family Foundation. Key Facts: Race, Ethnicity, and Medical Care. 2003. http://www.kff.org. Accessed April 12,2007.
26. Anonymous. The Impact of Fixed-dose Combinations on Blood Pressure Control, Persistence, and Comorbid Disease. Am J Manag Care. 2006:7-9.
27. Kaiser Family Foundation. Maryland State Medicaid Fact Sheets. 2004- 2005. http://www.kff.org/. Accessed March 3,2007.
28. Burnier M. Medication adherence and persistence as the cornerstone of effective antihypertensive therapy. Am J Hypertens. 2006:19:1190-1196.
29. Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987:40:373-383.
30. Martinez-Castelao A, Gorriz JL, Garcia-Lopez F, et al. Perceived health- related quality of life and comorbidity in diabetic patients starting dialysis (CALVIDIA study). J Nephrol. 2004:17:544-551.
31. Glynn RJ, Knight EL, Levin R, Avorn J. Paradoxical relations of drug treatment with mortality in older persons. Epidemiology. 2001;12:682-689.
32. Mark TL, Palmer LA, Russo PA, Vasey J. Examination of treatment pattern differences by race. Ment Health Serv Res. 2003:5:241-250.
33. Bosworth HB, Dudley T, Olsen MK, et al. Racial differences in blood pressure control: potential explanatory factors. Am J Med. 2006:119:70 e79-15.
34. Charles H, Good CB, Hanusa BH, Chang CC, Whittle J. Racial differences in adherence to cardiac medications. J Natl Med Assoc. 2003:95:17-27.
35. DiMatteo MR, Sherbourne CD, Hays RD, et al. Physicians' characteristics influence patients' adherence to medical treatment: results from the Medical Outcomes Study. Health Psychol. 1993:12:93-102.
36. Ogedegbe G, Harrison M, Robbins L, Mancuso CA, Allegrante JP. Barriers and facilitators of medication adherence in hypertensive African Americans: a qualitative study. Ethn Dis. 2004:14:3-12.
37. Sica DA. Rationale for fixed-dose combinations in the treatment of hypertension: the cycle repeats. Drugs. 2002;62:443-462.
38. Rudd P. Clinicians and patients with hypertension: unsettled issues about compliance. Am Heart J. 1995:130:572-579.
39. Taylor AA.Shoheiber 0. Adherence to antihypertensive therapy with fixed-dose amlodipine besylate/benazepril HCI versus comparable component-based therapy. Congest Heart Fail. 2003:9:324-332.
40. Messerli FH, Weir MR, Neutel JM. Combination therapy of amlodipine/ benazepril versus monotherapy of amlodipine in a practice-based setting. Am J Hypertens. 2002:15:550-556.
41. Thrall G, Lip GY, Lane D. Compliance with pharmacological therapy in hypertension: can we do better, and how? J Hum Hypertens. 2004:18:595- 597.
42. Degli Esposti L,Valpiani G. Pharmacoeconomic burden of undertreat- ing hypertension. Pharmacoeconomics. 2004;22:907-928.